These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12095169)

  • 21. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
    Singh R; Dominiecki ME; Jaffee EM; Paterson Y
    J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
    Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
    Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
    Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
    Taylor P; Gerder M; Moros Z; Feldmann M
    Cancer Immunol Immunother; 1996 Mar; 42(3):179-84. PubMed ID: 8640846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
    Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
    Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
    Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo protein expression and immune responses generated by DNA vaccines expressing mycobacterial antigens fused with a reporter protein.
    Quinn A; Jiang W; Velaz-Faircloth M; Cobb AJ; Henry SC; Frothingham R
    Vaccine; 2002 Aug; 20(25-26):3187-92. PubMed ID: 12163270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
    Disis ML; Scholler N; Dahlin A; Pullman J; Knutson KL; Hellström KE; Hellström I
    Mol Cancer Ther; 2003 Oct; 2(10):995-1002. PubMed ID: 14578464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2/neu DNA vaccination for breast tumors.
    Smorlesi A; Papalini F; Pierpaoli S; Provinciali M
    Methods Mol Biol; 2008; 423():473-85. PubMed ID: 18370223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does lens intrinsic membrane protein MP19 contain a membrane-targeting signal?
    Chen T; Li X; Yang Y; Erdene AG; Church RL
    Mol Vis; 2003 Dec; 9():735-46. PubMed ID: 14735063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
    Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
    J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein.
    Velaz-Faircloth M; Cobb AJ; Horstman AL; Henry SC; Frothingham R
    Infect Immun; 1999 Aug; 67(8):4243-50. PubMed ID: 10417198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.
    Wei WZ; Shi WP; Galy A; Lichlyter D; Hernandez S; Groner B; Heilbrun L; Jones RF
    Int J Cancer; 1999 May; 81(5):748-54. PubMed ID: 10328228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.
    Dimitriadis A; Gontinou C; Baxevanis CN; Mamalaki A
    BMC Cancer; 2009 Oct; 9():386. PubMed ID: 19878568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
    Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
    Charles LG; Xie YC; Restifo NP; Roessler B; Sanda MG
    World J Urol; 2000 Apr; 18(2):136-42. PubMed ID: 10854149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.
    Foy TM; Bannink J; Sutherland RA; McNeill PD; Moulton GG; Smith J; Cheever MA; Grabstein K
    Vaccine; 2001 Mar; 19(17-19):2598-606. PubMed ID: 11257398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.